Safety and Effectiveness of Orbera365™ Intragastric Balloon System

Recruiting now

Conditions studied: Obesity

In brief

This is a prospective, multi-center, standard of care registry offered to subjects in the EU only that have already agreed to receive the Orbera365™ Intragastric Balloon (IGB) System for weight loss. Subjects that agree to participate in the registry will have data reported associated with standard of care weight management visits during the time the device is implanted (in-dwell period), with an additional visit 30 days after the removal procedure.

Key facts

Study ID

NCT07062094

Run by

Boston Scientific Corporation

People needed

200

Starts

2026-04-07

Expected to finish

2028-05-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is ≥ 18 years of age
• Subject meets the indicated population for the device according to the Instructions for Use (IFU) including obese patients with the BMI of 30-50 kg/m2 for weight loss and patients with BMI 40 kg/m2 and above or a BMI of 35 kg/m2 with comorbidities before obesity or another surgery, unless contraindicated.
• Subject is able to read, understand, and sign a written Informed Consent Form to participate in the registry

You may not qualify if…

• Subject is planning on becoming pregnant during the one year following study device placement
• Subject will complete follow-up visits at a location that the treating physician does not practice
• Subjects who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
• Current use or use within the three months before the baseline visit of over-the-counter or prescribed weight loss supplements/medications.
• Subjects who have conditions that are contraindicated for Orbera365™ IGB System as per the IFU, including, but not limited to:
• The presence of more than one IGB at the same time.
• Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease
• Potential upper gastrointestinal bleeding conditions
• A large hiatal hernia of > 5cm or a hernia ≤ 5 cm associated with severe or intractable gastro- esophageal reflux symptoms
• A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope
• Achalasia, symptoms suggestive of delayed gastric emptying, or presence of any other severe motility disorder that that may pose a safety risk during placement or removal of the device.
• Gastric Mass.
• Severe coagulopathy.
• Taking aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants and not under medical supervision.
• Prior surgery involving the esophagus, stomach, and duodenum or bariatric surgery

Where it is running

• OB Klinika — Prague, Czechia (enrolling)
• EndoBes - Centre Medico Teknon — Barcelona, Spain (enrolling)
• Dorsia Clinic, Madrid Spain — Madrid, Spain (enrolling)
• Hôpital Avicenne — Bobigny, France
• UHCW NHS Trust — Coventry, West Midlands, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.